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Determination of Ganciclovir and Acyclovir in Human Serum using 
Liquid Chromatography-Tandem Mass Spectrometry 
Anne-Grete Märtson1, Kai van Hateren1, Gerben van den Bosch1, Tjip van der 
Werf2,3, Daan Touw1, Jan-Willem C Alffenaar1,* 
RESEARCH ARTICLE
OBJECTIVES: Currently there is no data about a liquid chromatography tandem 
mass spectrometry (LC-MS/MS) assay including ganciclovir and acyclovir using 
stable-isotopically labeled internal standards.
METHODS: A LC-MS/MS assay for measurement of ganciclovir and acyclovir 
using deuterated standards: ganciclovir-[2H5] and acyclovir-[
2H4] was developed. 
The selectivity and sensitivity, linearity, accuracy and precision, recovery, matrix 
effect, stability, total process efficiency, carry-over and dilution integrity 
were validated based on EMA and FDA guidelines. 
RESULTS: The retention time for ganciclovir was 1.1 min and for acyclovir 1.35 
min. Calibration curves were linear over a range of 0.1 to 20 mg/L and the cor-
relation coefficient (R2) was 0.99912 for ganciclovir and 0.99945 for acyclovir. 
The calculated accuracy was –2.0% to 3.1% for ganciclovir and –1.0% to 6.4% 
for acyclovir. Within-day precision ranged from 1.8% to 6.6% for ganciclovir and 
1.6 % to 6.5% for acyclovir and between-day precision 0% to 9.6% for ganciclo-
vir and 0% to 7.9% for acyclovir. 
CONCLUSIONS: A rapid and validated LC-MS/MS method was developed for 
measurement of ganciclovir and acyclovir in human serum which can be used in 
routine patient care and clinical research. 
KEYWORDS: LC-MS/MS, ganciclovir, acyclovir, cytomegalovirus, therapeutic 
drug monitoring.
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Herpes viruses are a huge burden on the health care system. Herpes simplex vi-
rus (HSV) is prevalent in over 60% and cytomegalovirus (CMV) in 40-80% of the 
population [1,2]. All herpes viruses are not cleared after infection. Most infected 
individuals suppress replication by their cell-mediated immunity [3]. Transplant re-
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cipients, whose immunity is compromised, are more vulnerable to CMV disease (retinitis, 
encephalitis, hepatitis etc.) which may lead to rejection of the transplanted organ and 
increase mortality [4,5]. 
Currently nucleoside analogues ganciclovir (intravenous) and the prodrug valganciclovir 
(oral), which is in vivo is metabolized to ganciclovir, are used for standard treatment and 
prophylaxis of CMV [6,7]. Ganciclovir 5 mg/kg or valganciclovir 900 mg twice daily are 
the dosing regimens suggested by international consensus [6]. Another nucleoside ana-
logue, acyclovir, is used for HSV type 1, 2 and varicella zoster virus (VZV) [8]. Acyclovir is 
recommended for immunocompetent patients diagnosed with HSV in a dose of 800 mg 
orally 5 times daily [9]. Unfortunately, both of these medications cause severe side effects 
and dosages must be adjusted during kidney failure [8,10–12]. 
The most dangerous side effects that occur during ganciclovir treatment are blood dis-
orders (neutropenia, leucopenia) and graft failure [13]. With extremely high viral loads 
(>100,000 copies/mL), there is a risk of acquiring resistance to ganciclovir [14]. Adequate 
exposure of ganciclovir is necessary to provide sufficient treatment response and avoid 
acquired resistance. Moreover, it is known that acyclovir may cause dose related acute 
kidney injury [8,10]. These are all factors that suggest measuring serum concentrations 
of ganciclovir and acyclovir i.e., applying therapeutic drug monitoring (TDM) may be 
beneficial to guide and individualize therapy. The appropriate dose is estimated based on 
through and peak concentrations and area under the curve values (AUC).
The target trough concentrations for ganciclovir in our hospital are 1-2 mg/L and 2-4 mg/L 
for prophylaxis and therapy, respectively. The target peak concentrations are in the range 
5-12.5 mg/L. These concentrations base on inhibitory concentration of CMV and phar-
macokinetic parameters from available studies [11,12,15–17]. The target trough concen-
tration range for acyclovir in our hospital is 0.5-1.5 mg/L and target peak concentration 
range is 5-15 mg/L [18].  
Different analytical procedures have been developed to measure ganciclovir and acy-
clovir drug concentrations. For example high performance liquid chromatography with 
fluorescence and UV detection [19–22] and liquid chromatography with (tandem) mass 
spectrometry detection [23–28] have been used to determine ganciclovir in plasma, se-
rum, urine, cell culture media and also intracellularly. 
LC-MS/MS has been used before for the assay of ganciclovir and acyclovir, however to 
our knowledge not analysed with the same assay [25–28]. Several authors used structural 
analogs as internal standards such as acyclovir for the assay of ganciclovir [26,27] . The 
drawback of a structural analog is that it does not have as similar properties to the mea-
sured and as a stable isotope-labeled standard. Moreover, acyclovir and ganciclovir are 
both included in antiviral protocol in transplant recipients. Therefore using an active drug 
for IS can interfere the determination of the drug under analysis [29], especially when 
both drugs like acyclovir and ganciclovir can be used in the same patient population.
One study used deuterated acyclovir, for the determination of acyclovir together with 
valacyclovir [25] and in another study fluconazole was used as IS [28]. Stable isotope-la-
beled IS have the advantage of possessing a similar structure to the original chemical 
compound with comparable extraction recoveries and chromatographic retention time. 
Therefore, using these aids to avoids any discrepancies and make the method more 
stable. 
LC-MS/MS was earlier used to analyse valacyclovir together with acyclovir [25,28]. Shi 
et al. (acyclovir, valacyclovir) reported run time of 9 minutes, Yadav et al. (acyclovir, va-
lacyclovir) 12 minutes and Xu et al. (ganciclovir) 5.5 minutes [25,27,28]. Yadav et al and 
Billat et al used solid phase extraction to determine acyclovir and ganciclovir, this method 
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is known to be more time-consuming and costly than direct protein precipitation [26,28]. 
In another assay, ganciclovir was measured with acyclovir as internal standard (IS) [24]. 
To our knowledge, no assay, is published where both acyclovir and ganciclovir are mea-
sured using LC-MS/MS and stable isotopically labeled IS for rapid throughput, has been 
published. Moreover, development of individual methods for each drug is more time con-
suming. Thus, using a single method with a high throughput for multiple drugs is more 
efficient. Furthermore, we aimed to develop this assay to be used in both for patient care 
and research purposes, provided that the validated assay meets the requirements of the 
TDM and study protocol. This study describes a rapid LC-MS/MS assay with deuterated 
internal standards for both ganciclovir and acyclovir.
MATERIALS AND METHODS 
Chemicals and reagents
Ganciclovir, ganciclovir-[2H5], acyclovir and acyclovir-[
2H4] were purchased from Alsa-
chim (Illkirch, France) (in Figure 1. chemical structures are presented). Purified water was 
obtained from a Milli-Q water purifying system (Millipore Corporation, Billerica, MA, USA). 
Acetic acid and ammonium acetate were received from Merck, NJ, USA and trifluoroace-
tic acid and acetonitrile were received from Biosolve, the Netherlands. Pooled human 
serum samples were obtained from local hospital according to the standard operating 
procedures of the medical center.   
 
Preparation of stock solutions, calibration standard and QC samples 
Stock solutions of 500 mg/L for ganciclovir and acyclovir were prepared by dissolving the 
compounds in methanol. Independent stock solutions were used to prepare calibration 
and internal quality control (QC) samples. For calibration samples blank human serum 
was used which was spiked to get 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 mg/L. QC sam-
MÄRTSON AG et al.
Figure 1. Chemical structures. (a) ganciclovir; (b) ganciclovir-[2H5]; (c) acyclovir; (d) acyclo-
vir-[2H4] 
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ples were prepared using blank human serum at lower limit of quantification (LLOQ) (0.1 
mg/L), low (0.3 mg/L), medium (10 mg/L), high (16 mg/L) and over-curve (OC, 40 mg/L). 
Samples were stored at -20°C until use. The IS solution was prepared by dilution of 100 
mg/L stock solution ganciclovir-[2H5] and acyclovir-[
2H4] until concentration 0.05 mg/L 
was obtained for both IS. 10 μL of serum was added to 500 μL of precipitation agents in-
cluding the IS. As the sample was diluted 50 times with the precipitation reagent the final 
IS concentration in the diluted sample was 2.5 mg/L. The final concentration, 2.5 mg/L, 
which is in the middle of the calibration curve. The IS was prepared in 10% trichloroacetic 
acid and that was used as matrix for the QC, calibration, analysis of patient samples and 
as precipitation reagent. 
Sample preparation 
To 10 μL serum of each sample, a volume of 500 μL of precipitation reagent combined 
with the deuterated IS were added in a vial. The samples were vortexed for 1 min. The 
vials were centrifuged for 5 min at 11,000 rpm. Five microliters of the upper layer was 
injected into the LC-MS/MS.
LC MS/MS system
The analysis was carried out on a triple quadrupole Thermo Fisher Scientific TSQ® Quan-
tum Access MAX LC-MS/MS system with a Surveyor® MS pump and a Surveyor plus® 
autosampler. A Thermo Fisher Scientific 50 mm × 2.1 mm C18, 5-μm HyPURITY Aquastar 
analytical column was used for the chromatographic separation, with a column tempera-
ture of 20°C. The autosampler temperature was set to 10°C. The mobile phase (pH 3.5) 
contained an aqueous buffer (A) (acetic acid 35 mL/L, ammonium acetate 5 g/L, and 
trifluoroacetic acid  2 mL/L), water (B) and acetonitrile (C). The flow rate was 0.3 ml/min. 
The gradient is shown in Table 1 and run time was 4.5 min. 
The mass spectrometer operated in Selected Reaction Monitoring (SRM) mode and pos-
itive mode was selected for electrospray ionization. The spray voltage was 3500 V, capil-
lary temperature 350°C and sheath gas pressure and auxiliary gas pressure were 35 and 
10 arbitrary units respectively. During the method all the voltages and column were on 
standard settings. Mass ion transitions for ganciclovir were 256.0 m/z →152.1 m/z and 
for ganciclovir-[2H5] 261.1 m/z →152.1 m/z and for acyclovir 226.0 m/z → 152.1 m/z and 
for acyclovir-[2H4] 230.1 m/z → 152.1 m/z while using a scan width of 0.5 m/z. Collision 
energies (CE) were 13 V (volts) for acyclovir, 14 V for acyclovir-[2H4], 13 V for ganciclovir 
and 16 V for ganciclovir-[2H5]. Product ion scans are shown in Figure 2. 
MÄRTSON AG et al..
Table 1. Gradient elution
Time (min) % elution
A B C
0.00 5 95 0
0.20 5 95 0
1.50 5 85 10
1.51 5 0 95
3.00 5 0 95
3.01 5 95 0
4.5 5 95 0
A = aqueous buffer (acetic acid 35 ml/L, ammonium acetate 5 g/L and trifluoroacetic acid 2 
mL/L), B = water, C = acetonitrile
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Figure 2. Product ion scans, (A) acyclovir 226.0 → 152.1 m/z (CE 13V) and (B) ganciclovir 256.0 → 152.1 m/z (CE 13V).
Method validation
The analytical method was validated based on European Medicines Agency (EMA) and 
US Food and Drug Administration (FDA) guidelines and the parameters that were de-
termined for validation were selectivity and sensitivity, linearity, accuracy and precision, 
recovery, matrix effect, stability, total process efficiency, carry-over and dilution integrity 
[30,31]. 
Linearity was tested with different serum concentrations (0.1, 0.5, 1, 2.5, 5, 10, 15, 20 
mg/L) for ganciclovir and acyclovir (for regression equations see Table 2). The validity 
of the regression analysis was determined with the calculation of residuals. The plotted 
residuals showed a random pattern hence the regression was valid.
For selectivity, 6 unpooled human blank serum samples were examined for interference. 
The responses of blank serum samples were compared to interference of the LLOQ sam-
ples. Every day for three consecutive days a single calibration curve was analysed and 
for accuracy QC samples were analysed in five-fold. Within-run and between-run preci-
sion were established using the same method as for accuracy. The accepted deviation for 
precision was a CV <15% and for accuracy a bias of maximally 15% of the nominal value. 
The accuracy and precision concentration bias and CV were calculated per run and were 
expected to be greater than 80% of the nominal value. After a high concentration (20 
mg/L) the carry-over was less than 20% of the LLOQ. 
The method of Matuszewski et al. was used to analyse matrix effects, recovery and total 
process efficiency at three concentrations (LOW, MED, HIGH) [32]. For the analysis of 
matrix effects the relative recovery was measured. This was done by comparing the ratios 
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of peak height of ganciclovir and acyclovir and the corresponding IS of the QC samples 
processed with the average peak height  of the LOW, MED and HIGH recovery samples. 
These were post-extraction blank serum samples that were spiked at the concentrations 
of the QC samples. For dilution integrity OC was diluted ten times with blank serum in 
five-fold. This was done for three consecutive days with every analyte concentrations 
above the HIGH.  
For storage stability the LOW and HIGH QC samples of ganciclovir and acyclovir were 
used. The samples were compared to fresh calibration curve for analysis. These sam-
ples were tested for stability at room temperature (144 hours 20-25°C), at refrigerator 
temperature (144 hours 4°C), in the autosampler (after processing of the sample, 120 
hours, 10°C) and in four freeze thaw cycles (-20°C). A limit of 15% of loss of the initial 
drug concentration was accepted. 
Clinical application of the method
This method has been used for TDM in routine care of patients receiving acyclovir and 
ganciclovir. Blood was collected from patients in a Clot Activator tube. For the analysis 
whole blood was centrifuged at 3,000 g for 5 min and minimum amount of 0.5 mL serum 
was collected and stored at -20°C. To 10 μL of serum a volume of 500 μL precipitation 
reagents combined with the deuterated IS were added into a vial. Samples were vortexed 
for 1 minute and centrifuged for 5 minutes at 11,000 x rpm. Five μL of the upper layer was 
injected into the LC-MS/MS. 
RESULTS
The retention time for ganciclovir was 1.1 min and for acyclovir 1.35 min (Figure 3). The 
chromatograms presented in Figure 3 were analysed and no interfering peaks at the 
retention time of ganciclovir, ganciclovir-[2H5], acyclovir, acyclovir-[
2H4] were observed 
using blank samples. 
The calibration curves were linear over a range of 0.1 to 20 mg/L and the correlation co-
efficient (R2) was 0.99912 for ganciclovir and 0.99945 for acyclovir.  The calibration lines 
are presented in Table 2. 
The calculated accuracy was –2.0% to 3.1% for ganciclovir and –1.0% to 6.4% for acy-
clovir. Within-day precision ranged from 1.8% to 6.6% for ganciclovir and 1.6 % to 6.5% 
for acyclovir and between-day precision 0% to 9.6% for ganciclovir and 0% to 7.9% for 
acyclovir (Table 3). The results of matrix effects, recovery and total process efficiency 
are presented in Table 3. 
Results of stability testing of ganciclovir and acyclovir QC samples LOW and HIGH are 
shown in Table 4. Bench top stability (144 hours) biased between 4.8% and 6.7% for 
Table 2. Regression equations  
Compound Y-intercept (± St.dev) Slope (± St.dev) Corr. coefficient
Ganciclovir 0.00290±0.00668 0.377±0.00338 0.99912
Acyclovir 0.00335±0.00579 0.413±0.00292 0.99945
St.dev = standard deviation; corr. = correlation.
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Figure 3. Chromatograms of  two analytes at LLOQ of  0.10 mg/L, two internal standards with a concentration of  0.05 mg/L along 
with blank: (a) ganciclovir; (b) acyclovir; (c) ganciclovir-[2H5]; (d) acyclovir-[
2H4]; (e) ganciclovir blank; (f) acyclovir blank.
MÄRTSON AG et al.
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Table 3. Validation results 
Criteria QC Concentration Level
Nominal Concentration (mg/L)
LLOQ LOW MED HIGH OC
Ganciclovir 0.1 0.3 10 16 40
Acyclovir 0.1 0.3 10 16 40
Accuracy (Bias (%))
Ganciclovir 0.1 2.8 -0.9 3.1 -2.0
Acyclovir 5.2 5.3 0.9 6.4 -1.0
Within-day precision (CV (%))
Ganciclovir 6.6 4.9 2.7 2.4 1.8
Acyclovir 6.5 5.0 2.7 1.9 1.6
Between-day precision (CV (%))
Ganciclovir 5.4 4.0 0.0 3.9 9.6
Acyclovir 3.4 0.0 1.1 2.9 7.9
Matrix effect (bias (%))
Ganciclovir n/a 8.8 5.5 1.6 n/a
Acyclovir n/a 5.2 5.1 1.1 n/a
Recovery (bias (%))
Ganciclovir n/a 99.8 95.0 97.0 n/a
Acyclovir n/a 95.0 95.7 97.1 n/a
Total process efficiency (bias (%))
Ganciclovir n/a 108.6 100.2 98.6 n/a
Acyclovir n/a 100.0 100.5 98.2 n/a
MÄRTSON AG et al.
183JOURNAL OF APPLIED BIOANALYSIS
ganciclovir and 5.6% and 6.2% for acyclovir; in a refrigerator 4°C (144 hours) biased 
between 9.1% and 12.1% for ganciclovir and 7.3% and 7.4% for acyclovir; and in the 
auto-sampler (120 hours) biased between 7.0% and 10.3% for ganciclovir and 7.0% and 
11% for acyclovir. Samples have proven to be stable after 1 year storage in -20°C.   
Clinical application results
In the period from April 2016 to September 2018, 65 acyclovir samples with the median of 
2 mg/L (IQR 0.9-5.4 mg/L) and 361 ganciclovir samples with the median of 2.2 mg/L (IQR 
1-3.9 mg/L) were measured. TDM for acyclovir was used to guide therapy in patients with 
kidney failure, receiving renal replacement therapy (RRT), virologic failure or to monitor 
oral absorption of the drug. The population for whom ganciclovir and valganciclovir TDM 
was used mainly consisted of transplant recipients and patients with human immunodefi-
ciency virus. TDM was indicated in kidney failure, during RRT, for complicated CMV cases 
and also to analyse oral absorption of valganciclovir. This assay participates in a profi-
ciency program and is being routinely controlled [33]. The testing program in our labora-
tory is done by the same organization as for antifungal and antiviral medications [34,35].
DISCUSSION
We describe a LC-MS/MS method for the determination of ganciclovir and acyclovir us-
ing deuterated ganciclovir-[2H5] and acyclovir-[
2H4] as IS. We present the first LC-MS/MS 
method where these compounds are measured with the same method using deuterated 
IS. 
Sample clean-up is a simple protein precipitation step. Using protein precipitation makes 
the method more efficient compared to solid phase extraction which has been used by 
Yadav et al. [28]. Furthermore, the rapid retention times of 1.1 min and 1.35 min for ganci-
clovir and acyclovir respectively and a method run time of 4.5 min improve time efficien-
Table 4. Stability results 
Criteria QC Concentration Level
LOW HIGH
Auto-sampler stability (after 120h) 
(bias %)
Ganciclovir 7.0  10.3
Acyclovir 7.0 11.0
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cy. The shorter run time and sample clean-up method, compared with previous studies, 
makes this applicable for routine patient care by optimizing and promoting high sample 
throughput [25,27,28]. Although UPLC can potentially shorten the runtime further, this 
method requires a higher sample load to benefit from the additional costs made for the 
method. 
The calibration curve was linear within a range of 0.1 to 20 mg/L which the acyclovir and 
ganciclovir predicted trough and peak concentrations in serum [16–18]. The upper limit 
is higher compared to Yadav et al. mainly because we also measure peak concentrations 
which can be higher than 10 mg/L [16,18,36]. These are determined in addition to trough 
concentrations and applied in pharmacokinetic modelling to determine the correct dose 
for the specific patient. During the method all the voltages and column remained at stan-
dard settings which makes it simple to change between different assays in the laboratory. 
There were no interfering peaks from endogenous substances using six pooled serum 
samples. As mentioned before, using the deuterated IS is a benefit as ganciclovir and 
acyclovir can be used in the same patient group. Thus in an assay where acyclovir is 
used as an IS while determining ganciclovir concentration the results might not be valid.
Our method is part of a proficiency testing program [33]. This ensures the safety and 
quality of this LC-MS/MS assay as it is an important part of QC. An interlaboratory profi-
ciency testing program is important for both clinical care and research. Moreover, an ad-
equate comparison between laboratories is necessary in both clinical care and research 
to have acceptable results.
Prevention of side effects and achieving better treatment outcomes are among others 
reasons for performing TDM for acyclovir and ganciclovir. There is currently a gap of 
knowledge whether routine TDM is indicated for either acyclovir or ganciclovir and the 
discussion is ongoing [16,35]. Prospective studies are needed to specify the patient pop-
ulation for whom TDM seems most appropriate. 
The short run time and small serum volume (10 μL) makes our LC-MS/MS assay a straight-
forward method, which is easy to apply in routine TDM and prospective pharmacokinetic 
studies. 
CONCLUSION 
A rapid and validated LC-MS/MS method was developed for the measurement of ganci-
clovir and acyclovir in human serum. Ganciclovir-[2H5] and acyclovir-[
2H4] were used as 
internal standards. The method is suitable for use in routine patient care and in clinical 
research.
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